Biotechnological companies using AI
NorthStrive Biosciences (NASDAQ: ELAB) announced on February 4, 2026, an update to the timeline for its AI development program's Phase III, in collaboration with Yuva Biosciences. The company now anticipates Phase III results in Q2 2026, an extension from the initial 6--9 week estimate, driven by enhanced sixth--generation classifier models improving screening accuracy. This development led to a significant positive market reaction, with the stock surging 15.92%.